AnaptysBio, Inc. (ANAB)
| Market Cap | 700.92M |
| Revenue (ttm) | 18.00M |
| Net Income (ttm) | -73.84M |
| Shares Out | 27.32M |
| EPS (ttm) | -2.71 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $26.11 |
| Previous Close | $25.63 |
| Change ($) | 0.48 |
| Change (%) | 1.87% |
| Day's Open | 26.47 |
| Day's Range | 25.81 - 27.36 |
| Day's Volume | 461,683 |
| 52-Week Range | 12.82 - 30.00 |
SAN DIEGO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging i...
AnaptysBio is a $675M clinical-stage biotechnology company focused on developing immunology therapeutics based around emerging immune control mechanisms applicable to inflammation and immuno-o...
SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging i...
SAN DIEGO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging i...
AnaptysBio (ANAB) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
AnaptysBio (ANAB) reports positive top-line data from an interim analysis of its phase II GALLOP study on imsidolimab for the treatment of moderate-to-severe generalized pustular psoriasis.
SAN DIEGO, Oct. 13, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging i...
SAN DIEGO, Sept. 11, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet m...
DENVER--(BUSINESS WIRE)--Shuman, Glenn & Stecker Investigates AnaptysBio, Inc.
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -5.33% and -100.00%, respectively, for the quarter ended June 2020.
SAN DIEGO, Aug. 10, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging...
AnaptysBio, Inc. (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
SAN DIEGO, Aug. 05, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet me...
Dermatology Physician-Scientist To Lead Wholly-Owned Pipeline Advancement Dermatology Physician-Scientist To Lead Wholly-Owned Pipeline Advancement
Appoints Dennis Mulroy as Chief Financial Officer and Eric Loumeau as Chief Operating Officer Appoints Dennis Mulroy as Chief Financial Officer and Eric Loumeau as Chief Operating Officer
SAN DIEGO, July 08, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging...
AnaptysBio, Inc. (ANAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
Is (ANAB) Outperforming Other Medical Stocks This Year?
The beaten-up biopharma provided an update that revved up interest in its pipeline.
NEW YORK, May 19, 2020 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in AnaptysBio, Inc. ("Anaptys" or the "Company") (NASDAQ:ANAB) of the May...
NEW YORK, May 15, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AnaptysBio, Inc. (NASDAQ: ANAB) between October 10, 2017 and N...
As of late, it has definitely been a great time to be an investor AnaptysBio
AnaptysBio (ANAB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
AnaptysBio, Inc. (ANAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
These three biopharma stocks all ended in positive territory Friday after a week of double-digit declines.
Worries about a coronavirus impact don't make sense.
A pair of black swans crushed these three healthcare stocks today.
After a rough 2019, investors are excited about the biotech's prospects in the year ahead.
AnaptysBio, Inc. (ANAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
Falling knives are companies whose share prices have declined more than 59% over the past 12 months.
AnaptysBio Is Due For A Bounce As It Trades Significantly Below Its Net Cash Per Share
AnaptysBio has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
AnaptysBio (ANAB) earnings for the antibody development company's third quarter of 2019 have ANAB stock taking a dive on Friday.
A clinical trial flop doesn't leave the biotech a lot of options.
AnaptysBio Inc (NASDAQ: ANAB) shares were taking a huge hit after the company announced a clinical pipeline update along with its third-quarter report.
AnaptysBio stock crashed Friday after the biotech said its experimental eczema treatment failed to pass muster in a Phase 2 study. Shares fell to their lowest-ever point in high volume.
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -2.68% and -100.00%, respectively, for the quarter ended September 2019.
SAN DIEGO, Nov. 08, 2019 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet me...
AnaptysBio, Inc. (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Top Ranked Momentum Stocks to Buy for October 31st
Investors have lost faith in the biopharma, which is sitting at its lowest market cap in two years. But Wall Street may be overlooking a significant catalyst from a partnered asset.
AnaptysBio (ANAB) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
The company released some positive data yesterday...that wasn't positive enough.
AnaptysBio Inc (NASDAQ: ANAB) released topline results Monday from an interim data analysis from a midstage study of its investigational asset ANAB019, which being evaluated for moderate-to-se...
AnaptysBio stock toppled Tuesday after the biotech company's psoriasis treatment failed to enthuse investors. The company tested just two patients vs.
SAN DIEGO, Sept. 30, 2019 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet m...
SAN DIEGO, Sept. 27, 2019 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet m...
An executive's departure at a sensitive time has investors nervous.
About ANAB
AnaptysBio, a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor for generalized pustular psoriasis and palmoplantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases. It is also developing immuno-oncology... [Read more...]
| Industry Biotechnology | IPO Date Jan 26, 2017 |
| CEO Hamza Suria | Employees 89 |
| Stock Exchange NASDAQ | Ticker Symbol ANAB |
Financial Performance
In 2019, AnaptysBio's revenue was $8.00 million, an increase of 60.00% compared to the previous year's $5.00 million. Losses were -$97.34 million, 57.9% more than in 2018.
Analyst Forecasts
According to 6 analysts, the average rating for AnaptysBio stock is "Buy." The 12-month stock price forecast is 28.00, which is an increase of 7.24% from the latest price.